VIDO/Bioniche E. coli 0157 Vaccine Shows Further Promise

BELLEVILLE ON - May 12, 2004 – Bioniche Life Sciences Inc., a fully-integrated human and animal health biopharmaceutical company, today announced that a controlled challenge study, performed at the Vaccine & Infectious Disease Organization (VIDO) at the University of Saskatchewan, has again demonstrated the efficacy of the E. coli 0157 cattle vaccine developed by the Company’s Food Safety division in partnership with VIDO, the University of British Columbia, and the Alberta Research Council.